Answers are grounded in this paper and cite their sources.
Background: Breast cancer is the most prevalence cause of cancer death among women and the fifth largest cause of cancer death globally, treatment of breast cancer include hormonal that can be change to other chemotherapy when the response is poor, Paclitaxel is the one of the most chemotherapy used in this reason which include Peripheral neuropathy which is the most adverse effect encountered by paclitaxel which may affect targets tubulin, and impairs mitotic spindle assembly, chromosome segregation, and cell division and quality of life of patient.The aim of this study was to evaluate the incidence of peripheral neuropathy among breast cancer women on paclitaxel. Patient and Methods:This is a cross sectional study of 100 postmenopausal women taken Paclitaxel-treated chemotherapy aged 45-75 years which admitted to oncology center of Imam Hussein teaching hospital in Kerbala city which presented in this study and clinical examination of the incidence and severity of peripheral neuropathy was done according to standard score, tumor marker Ca 15.3 was measurement of each patient as response mechanism to be associated with incidence of peripheral neuropathy. Results:The incidence of peripheral neuropathy was 82% in total according to the scoring Schedule (3-13) a severity scoring making significant hiher thab standard normal a strong negative correlation between Ca 15-3 levels in breast cancer patients and incidence of peripheral neuropathy which abnormal R.value=0.821. Conclusion:The incidence of peripheral neuropathy is Paclitaxel chemotherapy in taken to women have breast cancer was non response conduct relating a adverse effect with Ca 15.3 as continuous and effective measurement and close following up are required to control situation.
No takes yet. Share an insight, caveat, or question.
Sahib et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: